Fig. 5
From: A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
OS according to the nomogram total points (I–IV ranges). The groups were obtained considering the total point distribution of our population. Group I and II (red lines) represent patients with poor outcome